UPDATE : Friday, July 10, 2020
BNC to market Huons’ aesthetic medical device
  • By Lee Han-soo
  • Published 2018.01.29 11:22
  • Updated 2018.01.29 11:22
  • comments 0

Huons said Monday that it has signed a strategic partnership agreement with Brand New Cosmetics (BNC), an Australian aesthetic company, to exclusively distribute its Derma Shine Balance, an aqua shining injection device, in Australia.

Huons Global Marketing Director Ko Han-seok (left) and BNC Managing Director Jeff Chen pose after signing a strategic partnership agreement to exclusively market Derma Shine Balance in Australia, at Huons headquarters in Pangyo, Gyeonggi Province, on Jan. 17.

Derma Shine Balance is an upgraded version of the first-generation Derma Shine launched in Korea in 2014. The device has firmly established itself as one of the leading medical equipment for aqua shining injection. The device injects Elravie Balance, a high-polymer hyaluronic acid, into the entire face through a pressure-sensitive automatic injection system.

The company has steadily entered the global market since the China Food and Drug Administration (CFDA) approved the first-generation Derma Shine in 2014, and Derma Shine Balance received European CE mark in October. The company also plans to acquire CFDA approval for Derma Shine Balance in the first half of this year.

Regarding Australia, the company has already received certification from Australia’s Therapeutic Goods Administration (TGA) and is set to market its product from next month. Huons expects the TGA certification, recognized worldwide for its thorough and rigorous management system, will help its efforts to enter other major markets.

“Derma Shine Balance, which has won both CE certification in Europe and the TGA certification in Australia, is now ready to enter the overseas beauty market aggressively,” Huons CEO Um Key-an said. “The company plans to actively participate in the global aesthetic market through close cooperation with globally renowned aesthetic companies, including BNC.”


<© Korea Biomedical Review, All rights reserved.>

Other articles by Lee Han-soo
iconMost viewed
Comments 0
Please leave the first comment.
Back to Top